



#KCRS20 October 22-23, 2020
kcrs.kidneycan.org

A Focus on Translational Research

Thursday, October 22nd

4:00-7:15 p.m., with small group breakouts 7:30-8:30 p.m. EDT

3:00-4:00 p.m. EDT **Registration**

Please visit our sponsor displays!

4:00-4:10 p.m. EDT **Welcome, Introductions, & General Information**

4:10-4:40 p.m. EDT **Keynote: "Can Studies of the VHL Gene Get Us to Curative Combination Therapies for Kidney Cancer?"**
Dr. William Kaelin, Jr., Nobel Laureate
Harvard/Dana-Farber Cancer Institute

4:40-5:00 p.m. EDT **Keynote: Questions & Discussion**

5:00-6:00 p.m. EDT **The Next Frontier: New Molecular Targets for Kidney Cancer***
Moderated by Eric Jonasch, MD Anderson Cancer Center
& Naomi Haas, University of Pennsylvania

Mammalian Stringent Response Triggered by MESH1 Inhibition
Jen Tsan Chi, Duke University

TBK1 Serves as a Novel Therapeutic Target in Kidney Cancers with VHL Loss
Qing Zhang, University of Texas Southwestern

Targeting IGF1R Signaling in MTAP-Deficient Kidney Cancer
Ching-Hsien Chen, University of California Davis

Studying BAP1 in Regulating Glucose Dependency in Renal Cancer: Mechanisms and Preclinical Translation
Boyi Gan, MD Anderson Cancer Center

Getting the Right Therapies to the Right Patients: Emerging Biomarkers for Kidney Cancer*
Moderated by Sabina Signoretti, Dana Farber Cancer Institute
& Payal Kapur, University of Texas Southwestern

6:00-7:15 p.m. EDT

Characterizing and Targeting the Microenvironmental Barriers to Immunotherapeutic Response in RCC: Team Research
Ari Hakimi & Tim Chan, Memorial Sloan Kettering Cancer Center

Endogenous Retrovirus Expression, Chromatin Abnormalities, and Response to Immune Checkpoint Blockade in Clear Cell RCC
Shridar Ganesan, Rutgers Cancer Institute

Host Immune Signatures as Therapy Response Biomarkers in Metastatic Renal Cell
Ziad Bakouny, Dana Farber Cancer Institute

Development and Testing of Circulating-Free Methylation DNA as a Prognostic Biomarker for Recurrent Kidney Cancer
Daniel De Carvalho, Princess Margaret Cancer Centre

Biomarkers of IO in RCC: What Is an Ideal Industry-Academic Relationship?
Megan Wind-Rotolo, BMS Translational Medicine Team Lead

7:30-8:30 p.m. EDT **Discussion Options**

Main auditorium is open for discussion with speakers.

Small-group breakout on "Variant RCC Subtypes" moderated by Nizar Tannir, MD Anderson Cancer Center.

Continue the discussion live on Twitter using #KCRS20.

**Q & A and Panel Discussion following each topic and at end of session.*



#KCRS20 October 22-23, 2020
kcrs.kidneycan.org

A Focus on Translational Research

Friday, October 23rd

8:15-11:15 a.m. EDT, followed by optional CME session 12:00-1:30 p.m. EDT

7:00-8:15 a.m. EDT	Registration Please visit our sponsor displays!
8:15 EDT	Welcome, Introductions, & General Information
8:15-9:15 a.m. EDT	Best of 2020: Including Updates from ESMO* Moderated by Toni Choueiri, Dana Farber Cancer Institute & Brian Rini, Vanderbilt University Translational Science Updates from ESMO Tom Powles, Barts Cancer Centre Important Clinical Updates from ESMO Laurence Albiges, Institut Gustave Roussy The Ever-Changing Clinical Landscape of Kidney Cancer Therapies: Updates and Ongoing Trials Robert Motzer, Memorial Sloan Kettering Cancer Center
9:15-9:30 a.m. EDT	Break Please visit our sponsor displays!
9:30-11:00 a.m. EDT	The Next Generation of Immune Therapies* Moderated by Hans Hammers, University of Texas Southwestern & John Haanen, Netherlands Cancer Institute Targeted Pro-Inflammatory Prodrugs for the Immunotherapy of Kidney Cancer Hans Hammers, University of Texas Southwestern Oncolytic Single-Cycle Replicating Immunotherapies for Kidney Cancer Michael Barry, Mayo Clinic Personalized T-Cell Immunotherapy for Renal Cell Carcinoma Shreeram Akilesh, University of Washington Lessons in Immunotherapy Failures Ira Mellman, Genentech, Cancer Immunology
11:00-11:15 a.m. EDT	Session Closing & Sign-On Information for Optional CME
11:15 a.m.- 12:00 p.m. EDT	Lunch Break
12:00-1:30 p.m. EDT	Optional CME Session: "The Emerging Role of Biomarkers in mRCC: Selecting Patients and Predicting Response to Treatment" "Current Management of Localized RCC" Dr. Brian Shuch, University of California Los Angeles "Predicting Response to Immune Checkpoint Inhibition in RCC" Dr. David Braun, Dana Farber Cancer Institute "Putting It All Together: Future Role of Biomarkers in Predicting mRCC Treatment Response" Dr. Hans Hammers, University of Texas Southwestern

**Q & A and Panel Discussion following each topic and at end of session.*